Autor: "Kümmerle, Tim" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study.
Autorzy:: Olliges E; Department of Psychosomatic Medicine and Psychotherapy, Klinik Barmelweid AG, Barmelweid, Switzerland.
Bührlen B; Psymeta GmbH, Clinical Research Organisation, Schafisheim, Switzerland.
Fischer F; Psymeta GmbH, Clinical Research Organisation, Schafisheim, Switzerland.
Boesecke C; Bonn University Hospital, Bonn, Germany.
Kümmerle T; Private Practice am Ebertplatz, Köln, Germany.
Schneider J; School of Medicine, University Hospital rechts der Isar, Technical University of Munich, Munich, Germany.
Weidlich S; School of Medicine, University Hospital rechts der Isar, Technical University of Munich, Munich, Germany.
Cordes C; Private Practice, Berlin, Germany.
Heiken H; Private Practice, Hannover, Germany.
Stellbrink HJ; ICH Study Center, Hamburg, Germany.
Krznaric I; Private Practice, Berlin, Germany.
Scholten S; Private Practice Hohenstaufenring, Köln, Germany.
Jensen BE; University Hospital Düsseldorf, Düsseldorf, Germany.
Wolf E; MUC Research, Munich, Germany.
Ronel J; Department of Psychosomatic Medicine and Psychotherapy, Klinik Barmelweid AG, Barmelweid, Switzerland.; Department of Psychosomatic Medicine and Psychotherapy, University Hospital rechts der Isar, Technical University of Munich, Munich, Germany.
Spinner CD; School of Medicine, University Hospital rechts der Isar, Technical University of Munich, Munich, Germany.
On Behalf Of The Dualis Study Group; Department of Psychosomatic Medicine and Psychotherapy, Klinik Barmelweid AG, Barmelweid, Switzerland.; Pokaż więcej
Źródło:: AIDS care [AIDS Care] 2022 Jun; Vol. 34 (6), pp. 698-707. Date of Electronic Publication: 2021 Apr 25.
Typ publikacji:: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
Darunavir/pharmacology ; Darunavir/therapeutic use ; Heterocyclic Compounds, 3-Ring ; Humans ; Middle Aged ; Oxazines ; Piperazines ; Pyridones ; Quality of Life ; Ritonavir/pharmacology ; Ritonavir/therapeutic use ; Viral Load

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance.
Autorzy:: Wolf E; MUC Research, Clinical Research Organization (CRO), Waltherstr. 32, 80337, Munich, Germany.
Boesecke C; Bonn University Hospital, Venusberg-Campus 1, 53127, Bonn, Germany.
Balogh A; MUC Research, Clinical Research Organization (CRO), Waltherstr. 32, 80337, Munich, Germany.
Bidner H; Munich Study Center, School of Medicine, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Cordes C; Private Practice, Warschauer Str. 33, 10243, Berlin, Germany.
Heiken H; Private Practice Georgstrasse, Georgstr. 46, 30159, Hannover, Germany.
Krznaric I; Private Practice, Zentrum Für Infektiologie Prenzlauer Berg, Berlin, Germany.
Kümmerle T; Private Practice Am Ebertplatz, Ebertplatz 1, 50668, Köln, Germany.
Stellbrink HJ; ICH Study Center, Grindelallee 35, 20146, Hamburg, Germany.
Schneider J; School of Medicine, University Hospital Rechts Der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany.
Spinner CD; School of Medicine, University Hospital Rechts Der Isar, Technical University of Munich, Ismaninger Str. 22, 81675, Munich, Germany. .; Pokaż więcej
Corporate Authors:: DUALIS Study Group
Źródło:: AIDS research and therapy [AIDS Res Ther] 2021 Sep 08; Vol. 18 (1), pp. 58. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji:: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV-1*/genetics
Darunavir/therapeutic use ; Drug Resistance ; Female ; Heterocyclic Compounds, 3-Ring ; Humans ; Male ; Middle Aged ; Oxazines ; Piperazines ; Pyridones

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study.
Autorzy:: Spinner CD; Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Munich, Germany.
Kümmerle T; Private Practice, Ebertplatz, Germany.
Schneider J; Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Munich, Germany.
Cordes C; Private Practice, Berlin, Germany.
Heiken H; Private Practice, Georgstrasse, Hannover, Germany.
Stellbrink HJ; ICH Study Center, Hamburg, Germany.
Krznaric I; Private Practice, Zentrum für Infektiologie Prenzlauer Berg, Berlin, Germany.
Scholten S; Private Practice, Hohenstaufenring, Köln, Germany.
Jensen B; University Hospital Düsseldorf, Düsseldorf, Germany.
Wyen C; Private Practice, Ebertplatz, Germany.; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
Viehweger M; Private Practice, Berlin, Germany.
Lehmann C; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
Sprinzl M; Department of Medicine I, University Hospital Mainz, Mainz, Germany.
Stoehr A; Private Practice, IfI Institute, Hamburg, Germany.
Bickel M; Private Practice, Infektiologiukum, Frankfurt, Germany.
Jessen H; Private Practice, Jessen2, Berlin, Germany.
Obst W; Department of Gastroenterology, University Hospital Magdeburg, Magdeburg, Germany.
Spornraft-Ragaller P; University Hospital Dresden, Fetscherstr, Germany.
Khaykin P; Private Practice, MainFachArzt, Frankfurt, Germany.
Wolf E; MUC Research Clinical Research Organization (CRO), Munich, Germany.
Boesecke C; Bonn University Hospital, Bonn, Germany.; Pokaż więcej
Corporate Authors:: DUALIS Study Group
Źródło:: Open forum infectious diseases [Open Forum Infect Dis] 2020 Aug 13; Vol. 7 (9), pp. ofaa356. Date of Electronic Publication: 2020 Aug 13 (Print Publication: 2020).
Typ publikacji:: Journal Article